Journal of cancer research and therapeutics最新文献

{"title":"Prospective evaluation of small bowel dose and acute gastrointestinal toxicity during pelvic radiotherapy for gynaecologic malignancies.","authors":"Febin Antony, Maria Philip, C Jomon Raphael, K Mathew Varghese, B Rajkrishna, Mathew P Jiniw, Minu Boban, Varun Narayan","doi":"10.4103/jcrt.jcrt_2378_24","DOIUrl":"10.4103/jcrt.jcrt_2378_24","url":null,"abstract":"<p><strong>Introduction: </strong>Acute gastrointestinal (GI) toxicity is common in patients receiving pelvic radiotherapy (RT) and the small bowel (SB) is a dose-limiting organ at risk. There is a quandary in the dose constraints for SB while using intensity-modulated radiotherapy (IMRT) for gynecological malignancies.</p><p><strong>Objectives: </strong>To investigate the correlation between the radiation dose received by SB and the incidence of acute lower GI toxicities, and to identify dose parameters that may reduce toxicity risk.</p><p><strong>Materials and methods: </strong>Fifty-eight patients diagnosed with gynecological cancers and received RT with IMRT technique were analyzed in this prospective observational study. Oral contrast was administered during the simulation scan as per institution protocol. The individual SB loops were delineated as per Radiation Therapy Oncology Group (RTOG) consensus guidelines. The volume of SB (cc) receiving 10, 15, 20, 30, and 40 Gy were analyzed. Grades of acute GI toxicities were assessed weekly according to RTOG scoring criteria. The odds of developing GI toxicities were analyzed using a logistic regression test.</p><p><strong>Results: </strong>Out of the study population, 26 patients (45%) were diagnosed with carcinoma of the cervix, and 32 patients (55%) were diagnosed with carcinoma of the endometrium. 33 patients (57%) also received concurrent chemotherapy. Overall, Grade I, II, and III GI toxicities were observed in 32%, 62%, and 5% of patients, respectively. None of the patients developed GI toxicity during weeks 1 and 2 of RT. A significantly higher incidence of ≥grade 2 GI toxicity was observed with a mean SB-V30 Gy >210 cc (P = 0.001) and SB-V40 Gy >103 cc (P = 0.001). Patients with SB-V30 Gy ≥210 cc had 2.2 times higher odds of developing ≥ grade 2 enteritis compared to those with SB-V30 Gy <210 cc (OR = 2.2; 95% CI, 1.5-6.3; P = 0.003). Likewise, the odds of developing ≥grade 2 enteritis were 2.9 times higher in patients with SB-V40 Gy ≥103 cc compared to those with SB-V40 Gy <103 cc (OR = 2.90; 95% CI, 2.1-5.1; P = 0.002).</p><p><strong>Conclusions: </strong>Higher radiation doses to individual SB loops lead to a decrease in cellular reserves of intestinal mucosa resulting in ≥grade 2 acute GI toxicity in patients receiving IMRT for gynecological malignancies.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 3","pages":"644-648"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144568241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Target volume definition of lung cancer between PET-CT and CT-based dosimetric planning.","authors":"Priya Tawri, Shankar L Jakhar, Guman Singh, Neeti Sharma, H S Kumar, M Athiyaman, A Hemalatha, Rajshekhar Agnivashya, Kanika Jain","doi":"10.4103/jcrt.jcrt_1448_24","DOIUrl":"10.4103/jcrt.jcrt_1448_24","url":null,"abstract":"<p><strong>Background: </strong>Lung cancer is the most common cancer worldwide with an incidence and mortality of 12.4% and 18.7%, respectively. Positron emission tomography-computed tomography (PET-CT) helps in both downstaging T criteria and upstaging disease by detection of distant extrathoracic or nonregional nodal metastases.</p><p><strong>Aim: </strong>The study is intended to compare target volume definitions between PET-CT and CT-based dosimetric planning for lung carcinoma patients on specific treatment planning parameters like tumor volumes and the number and location of involved nodes.</p><p><strong>Methodology: </strong>It was a prospective observational study done on 50 histologically proven, non-small-cell lung carcinoma patients. Two sets of target volumes were contoured independently - one based on the fused PET-CT images and the other based on CT alone.</p><p><strong>Results: </strong>The gross tumor volume on CT-based contours was 130.84 cc and that with PET was 95.84 cc, with an overall mean reduction of 35 cc on PET-CT as compared to CT, which was statistically significant with a P value of 0.004. A similar trend was seen with clinical target volume with a P value of 0.005. There was no significant difference seen in the normal tissue dose, represented by V20 (P = 0.418), mean lung dose (P = 0.185), and mean esophageal dose (P = 0.142) between PET-CT and CT-derived plans.</p><p><strong>Conclusion: </strong>FDG-F18 PET-CT is a valuable tool in the management of patients with non-small-cell lung cancer. It demonstrated advantages in reducing radiation doses to critical organs compared to CT, suggesting improved sparing of normal tissues while maintaining effective tumor targeting.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 3","pages":"547-550"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144568243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the efficacy of automated machine learning enhanced planning system and a comparative analysis with manual planning system.","authors":"Anand Jadhav, Ajinkya Gupte, Sachin Rasal, Omkar Awate, Prasad Raj Dandekar","doi":"10.4103/jcrt.jcrt_1373_24","DOIUrl":"10.4103/jcrt.jcrt_1373_24","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;The aim of radiotherapy treatment is to deliver a high dose of radiation precisely to the target volume while minimizing exposure to the surrounding organs at risk. This approach maximizes the likelihood of tumor control and reduces the risk of adverse side effects. Treatment planning systems (TPS) are crucial in achieving this goal. However, the manual planning process is time-consuming, resource-intensive, and subject to variability based on the skill and experience of individual planners. Automated planning aims to reduce inter-plan variation and planning duration while maintaining or improving plan quality. Varian Medical Systems introduced the Ethos platform, an automated planning and delivery system utilizing an Intelligent Optimization Engine (IOE). This study evaluates the efficacy of automated plan generation using the Varian Ethos IOE for prostate cancer treatment, compared with plans generated using the Eclipse TPS with the anisotropic analytical algorithm (AAA).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Materials and methods: &lt;/strong&gt;Fifteen retrospective patients diagnosed with prostate cancer, treated with a dose of 60 Gy in 20 fractions to the prostate, were included. Treatment approved Eclipse plans were recalculated and reoptimized with the same objective function, and then exported to the Ethos TPS. The Ethos TPS generates a total of five plans-7-, 9-, and 12-field IMRT plans, and 2- and 3-arc VMAT plans, respectively, maintaining fixed beam geometry. Two additional plans were also generated on Ethos: one maintaining identical parameters from Eclipse for calculation purposes, and a second involving re-optimization. The primary objective was to assess the number of prespecified dose constraints met, while the secondary objective was to compare dosimetric parameters, such as target coverage, dose conformity, dose homogeneity, and OAR sparing between the Ethos and Eclipse plans.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;There was no statistically significant difference between the Eclipse plan and the Ethos-generated plans in meeting the prespecified criteria. For PTV coverage, mean values for V95 &gt; 95% were achieved across all plans. The mean values for V105 &lt; 5% were well below the threshold, indicating minimal hotspots. The conformity index (CI) was close to 1, and the homogeneity index (HI) was close to 0 across all plans, indicating good dose distribution and uniformity. OAR sparing for the urinary bladder, rectum, and penile bulb was within acceptable limits, meeting dose constraints in all plans. Monitor unit (MU) values were higher for Ethos plans compared to Eclipse but remained within clinically acceptable ranges.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;The Ethos TPS, using its IOE, demonstrated the capability to generate high-quality radiotherapy plans for prostate cancer that are comparable to those produced by the Eclipse TPS. This suggests that the automated planning system can effectively reduce planning time and resource co","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 3","pages":"593-601"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144568269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mathematical analysis of gamma index on pretreatment patient-specific quality assurance with octavius 4D rotational phantom for 2d and 3d space.","authors":"Shilpa Tiwari, Vindhyavasini Prasad Pandey, Teerthraj Verma, Devi Prasad Pandey, Ghizal Firdous Ansari","doi":"10.4103/jcrt.jcrt_1766_24","DOIUrl":"10.4103/jcrt.jcrt_1766_24","url":null,"abstract":"<p><strong>Introduction: </strong>Gamma index is one of the widely used metrics to evaluate the patient-specific quality assurance parameters for the delivery of accepted treatment plans. The dimensionality of gamma metric has changed from two-dimensional to three-dimensional with due course of time, and presently, we are in a verge to assess the three-dimensional metric in a volumetric scale. The present study aimed at determining the mathematical relationship between 2D, 3D, and 3D volumetric gamma index for patient-specific quality assurance parameters using the Octavius 4D rotational phantom.</p><p><strong>Methods and materials: </strong>Twenty-five patients planned with volumetric modulated radiotherapy for different sites were selected for the study to analyze the pretreatment parameters correlation using 2D- Array 1500 rotational Octavius phantom. The data were collected in both local and global dose modes at 5%/5 mm, 4%/4 mm, 3%/3 mm, and 2%/2 mm for 2D, 3D, and Volmetric 3D gamma index. The passing criterion of Gamma <=1.0 is applicable throughout the study.</p><p><strong>Results: </strong>A significant jump in the passing rate percentage was found from 2D planar to 3D planar mode analysis. Decreased passing percentage values in both local and global modes from 3D planar to 3D volumetric mode analysis were recorded. The 2D and 3D planar analysis shows a significant level of correlation which is less pronounced in 3D planar to 3D volumetric gamma metric evaluation.</p><p><strong>Conclusion: </strong>The radiotherapy centers having the license for 2D planar gamma index analysis can retrace the results into 3D planar analysis, which is always a better passing percentage rate, and no such implication of 3D volumetric analysis was found as the passing rate significantly shows a high degree of entropy in results. The effective use of 3D volumetric gamma metric can be appreciable if the CT overlay parameter is used in assessment and qualitatively the quantification can be predicted.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 3","pages":"657-663"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144568277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adenoid cystic carcinoma of the lacrimal gland: A rare case report with literature review.","authors":"Anurag Singh, Shalini Rawat, Mala Sagar, Uma S Singh","doi":"10.4103/jcrt.jcrt_214_24","DOIUrl":"10.4103/jcrt.jcrt_214_24","url":null,"abstract":"<p><strong>Abstract: </strong>Adenoid cystic carcinoma (ACC) primarily originates from the minor and major salivary glands of the head and neck regions. ACC affecting the eye and orbit (including the lacrimal gland, sac, and duct) was determined to account for about 1.8% of all cases. A poor overall prognosis and a tendency for local recurrence and metastasis despite vigorous therapy characterize lacrimal gland ACCs. There are no clear-cut guidelines for treating these rare tumors in unusual places, but recent literature suggests orbital excision with or without bone removal instead of globe-sparing resection and adjuvant radiation therapy. In this case study, we show an unusual case of an ACC in the left superolateral orbit with the demonstration of clinical, radiological, morphology, and immunohistochemistry findings along with management protocols and a review of the relevant literature.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 3","pages":"716-719"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144568257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A giant peritoneal mesothelioma extending to the pelvic floor: A case report and review of the literature.","authors":"Mathew Thomas, Harikrishnan Nandakumar, Parth Sampat, Stephen Graziano","doi":"10.4103/jcrt.jcrt_247_24","DOIUrl":"10.4103/jcrt.jcrt_247_24","url":null,"abstract":"<p><strong>Abstract: </strong>Malignant peritoneal mesothelioma (MPM) is a rare malignancy originating from the peritoneal serosa and is the second most common site of mesothelioma after the pleura. Localized disease presents as a focal circumscribed mass, whereas diffuse disease is usually associated with ascites and may metastasize to abdominal and pelvic lymph nodes. Cytoreductive surgery with heated intraperitoneal chemotherapy has been shown to improve progression-free survival and overall survival. Systemic chemotherapy with pemetrexed and platinum-based chemotherapy has also demonstrated a good treatment response. Recently, there has been an increased interest in the use of immune checkpoint inhibitors in the treatment of MPM. We present the case of a 59-year-old female with progressively worsening abdominal pain and constipation, who on further evaluation was found to have a huge MPM (17.3 × 17.1 × 13.3 cm) extending into the pelvic cavity with associated compression of the vagina, sigmoid colon, and ureters complicated by bilateral hydronephrosis. The tumor was deemed unresectable, and the patient was started on dual immunotherapy with ipilimumab and nivolumab. The patient had symptomatic improvement and a reduction in tumor size to 15.1 × 11 × 8.6 cm. Despite the initial response, the disease progressed (15.6 × 13.8 × 23.8 cm) and the patient ultimately succumbed to it. This case highlights the unique presentation of a massive localized MPM and emphasizes the need for further research to optimize treatment strategies.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 3","pages":"739-742"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144568252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A prospective comparative study of pre-op chemoradiotherapy followed by surgery versus upfront surgery followed by adjuvant chemoradiotherapy in locally advanced borderline resectable oral cavity cancer.","authors":"Aishna, Surabhi Gupta, Akhil Pratap Singh, Varun Agrawal","doi":"10.4103/jcrt.jcrt_1317_24","DOIUrl":"10.4103/jcrt.jcrt_1317_24","url":null,"abstract":"<p><strong>Introduction: </strong>Patients diagnosed with oral cavity cancers (OCCs) often delay seeking medical attention and so always pose a challenge for oncologists. Typically, surgery is the preferred initial treatment option. However, surgical resection may not be feasible in cases of advanced disease. Conversely, radiotherapy (RT) and chemotherapy (CT) have not been widely used as alternatives to surgery for curative treatment or as neoadjuvant therapy.</p><p><strong>Objectives: </strong>This study aims to evaluate the clinical and pathological responses at both primary and regional sites, post-op margin status, and postoperative morbidity in locally advanced borderline resectable oral cavity cancer patients treated with neoadjuvant chemoradiotherapy (NACRT).</p><p><strong>Methods: </strong>Fifty-seven patients presenting with locally advanced borderline resectable OCC were randomly assigned to Arm A (neoadjuvant chemoradiotherapy followed; surgery was performed after 2 to 6 weeks) and Arm B (definite surgery followed by adjuvant radiotherapy with or without chemotherapy).</p><p><strong>Results: </strong>In our study, out of 26 patients in Arm A, 3 (11.53%) and 16 (69.55%) had pathological complete responses at the primary and nodal sites, respectively, and 19 (73.77%) and 5 (21.75%) had partial responses at the primary and nodal sites, respectively. A significant difference was observed in margin negativity compared with the standard arm; 22 (84.60%) patients achieved negative margin post-NACRT. Postoperative morbidity was comparable in both arms.</p><p><strong>Conclusion: </strong>The research findings indicate that the combination of NACRT and subsequent surgery is a viable option, resulting in favorable pathological complete responses. Given the significance of response to chemoradiotherapy as a prognostic indicator, these outcomes could potentially lead to improved disease-free survival rates in the future.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 3","pages":"567-575"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144568253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the cause and effects of objective function variation approach on volumetric modulated arc radiosurgery of solitary brain metastasis for efficient dosimetry.","authors":"Shabbir Ahamed, R Padma Suvarna, Navin Singh","doi":"10.4103/jcrt.jcrt_2205_24","DOIUrl":"10.4103/jcrt.jcrt_2205_24","url":null,"abstract":"<p><strong>Purpose: </strong>To demonstrate the cause and effects of dose gradients in normal brain and resulting plan metrics using varied objective functions for generating efficient volumetric modulated arc radiosurgery plans for solitary brain metastasis.</p><p><strong>Materials and methods: </strong>Normal tissue and dose volume objective function (NTO and DVO) variations were applied to the virtual phantom and 23 solitary brain metastasis (SBM) cases to plan 20 Gray (Gy) doses. Initial testing on the phantom used eight variations manipulating NTO priority (50, 100, 150, 200), end-dose (25% and 10%), and DVO target dose maximum (25 and 27 Gy). Two strategies were then tested on SBM cases. First strategy (S1) used NTO priority = 100, end-dose = 25%, target maximum dose < 25 Gy. The second strategy (S2) tightened NTO and relaxed DVO by changing the corresponding parameters to 200 and 10%, and 27 Gy. Plans were analyzed comparing and correlating relevant metrics.</p><p><strong>Results: </strong>For the phantom case, the mean multi-leaf collimator aperture area (AA) variation between the highest NTO priority S2 plan and lowest priority S1 plan was about 46%, which brought substantial changes to 12 Gy spill outside tumor (V12), efficiency index, and prescription isodose level (PIDL). SBM cases showed about 14% lower PIDL and associated V12 reduction of about 0.7 cm3 for S2 than S1. V12 reduction was explained by AA reduction (r ≥ 0.966). For the studied PTVs, monitor units per Gy (MU/Gy) and AA product were lower for S2 indicating one or either factor was lower.</p><p><strong>Conclusion: </strong>Stringent NTO and relaxed DVO functions cause aperture shrinkage to create dose gradients for overall plan efficacy.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 3","pages":"693-699"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144568260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Duodenal obstruction secondary to metastatic breast cancer.","authors":"Robert S O'Neill, Andrew Field, Bong Sik M Kim, Jorgen S Ferguson, Simon Ghaly, Rachel F Dear","doi":"10.4103/jcrt.jcrt_2022_24","DOIUrl":"10.4103/jcrt.jcrt_2022_24","url":null,"abstract":"<p><strong>Abstract: </strong>Breast cancer is the most common malignancy affecting females and is a leading cause of cancer-related mortality worldwide. The most common sites of metastatic disease are bone, liver, lung and brain, with the gastrointestinal tract less commonly implicated. Intestinal metastasis from breast cancer is rare, with vast majority of patients being asymptomatic. Diagnosis can often be delayed due to gastrointestinal symptoms perceived to be secondary to treatment rather than malignancy. Unfortunately, intestinal metastasis is associated with a poor prognosis with the median survival being 12 months. We present the case of a 53-year-old female with a diagnosed history of metastatic breast cancer who presented to our institution with nausea, vomiting and abdominal pain and was subsequently diagnosed with a small bowel obstruction secondary to duodenal metastasis after endoscopic ultrasound-guided tissue acquisition. She was managed conservatively with chemotherapy resulting in resolution of her small bowel obstruction.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 3","pages":"755-757"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144568268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A rare presentation of a cutaneous metastasis from an undifferentiated pleomorphic sarcoma.","authors":"M Harish, Ambedkar Yadala, Rashmi P Joshi, R Parameswari","doi":"10.4103/jcrt.jcrt_1771_24","DOIUrl":"10.4103/jcrt.jcrt_1771_24","url":null,"abstract":"<p><strong>Abstract: </strong>Undifferentiated pleomorphic sarcoma, a rare and aggressive soft tissue sarcoma, commonly affects the extremities and has a high propensity for local recurrence and metastasis. This case study presents a 57-year-old male with UPS in the right forearm, which progressed to rare cutaneous metastasis on the right chest wall following initial treatment. Despite undergoing wide local excision, flap reconstruction, and adjuvant radiation, the patient later developed disseminated metastases, including in the lungs, bones, liver, and skin. Immunohistochemistry confirmed metastatic pleomorphic sarcoma, leading to palliative chemotherapy. This case highlights the rarity of cutaneous metastasis in UPS, documented in less than 1% of cases, and underscores the diagnostic challenges posed by undifferentiated or poorly differentiated sarcomas. Timely diagnosis and multidisciplinary treatment are crucial in managing this aggressive malignancy, particularly when it presents with rare metastasis patterns. Further research is necessary to better understand UPS and improve therapeutic strategies.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 3","pages":"743-745"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144568255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}